drugset / Trial / NCT06087263
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
NaSingle-groupOpen-labelTreatment
Summary
To learn if regorafenib can help to control the disease.
Timeline
- Start
- 2024-06-18
- Primary completion
- 2032-07-01
- Completion
- 2034-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | — | Oral |